INTRODUCTION
============

Microsatellite instability (MSI), which is caused by the loss of DNA mismatch repair (MMR) activity, has a role in gastrointestinal (GI) carcinogenesis.[@b1-gnl-10-220] MSI is associated mainly with the contraction or expansion of microsatellite sequences due to the frequent replication errors caused by MMR mutations and tumor suppressor genes.[@b2-gnl-10-220] MSI is implicated in 8% to 39% of all gastric cancers, and in 15% of colorectal cancers.[@b3-gnl-10-220],[@b4-gnl-10-220]

Gastric cancers with MSI tend to be associated with old age, an antral location, Lauren's intestinal-type, and a high standard uptake value on 18fluoro-deoxyglucose positron emission tomography imaging.[@b5-gnl-10-220]--[@b9-gnl-10-220] On the other hand, colorectal cancers with MSI tend to be associated with female gender, a proximal location, a mucinous phenotype, and an ulcerated appearance.[@b3-gnl-10-220],[@b10-gnl-10-220]--[@b12-gnl-10-220] Both gastric and colorectal cancers with MSI are related to large-sized tumors, poor response to 5-fluorouracil chemotherapy, less metastasis, good prognosis, and increased metachronous neoplasms.[@b13-gnl-10-220]--[@b17-gnl-10-220] Synchronous colorectal neoplasm has recently been reported in gastric cancer patients.[@b18-gnl-10-220],[@b19-gnl-10-220] It was recommended that preoperative colonoscopy should be conducted to screen for colorectal neoplasm in gastric cancer patients over 50 years of age,[@b18-gnl-10-220] whereas another study found that a family history of gastric cancer is a risk factor for the development of colorectal neoplasm in those younger than 50 years.[@b19-gnl-10-220] Therefore, the predictors of synchronous GI neoplasm in gastric or colorectal cancer patients remain a matter of debate.

The aim of this study was to clarify whether MSI is a useful marker for predicting synchronous gastric and colorectal neoplasms. In addition, the prevalence of synchronous gastric or colorectal neoplasm in gastric and colorectal cancer patients with MSI was analyzed.

MATERIALS AND METHODS
=====================

1. Study subjects
-----------------

Consecutive gastric or colorectal cancer patients who underwent complete surgical resection between August 2005 and June 2013 at our center were enrolled. Inclusion criteria were subjects who underwent esophagogastroduodenoscopy (EGD) and colonoscopy before surgery and those who agreed with genetic analysis for MSI. Subjects were excluded when there is a known genetic disease such as hereditary nonpolyposis colorectal cancer (HNPCC) or familial adenomatous polyposis. To exclude any possibility of HNPCC, data on family history, past history, and presence of double primary malignancy were collected. In addition, those who underwent endoscopic resection for gastric or colorectal cancer were excluded from the study. Synchronous lesion was defined as another gastric or colorectal neoplasm(s) found within 12 months before or after the surgery.

All of the patients provided informed consent before undergoing the endoscopic procedure and MSI analysis, and the study was approved by Institutional Review Board of Konkuk University School of Medicine which confirmed that the study was performed in accordance with the ethical standards of the Helsinki Declaration (KUH 1010266). After the IRB approval, this study was registered in the Korean Clinical Trial Registry as ClinicalTrials.gov ID KCT0000948. All of the authors accessed to the study data and had reviewed and approved the final manuscript.

2. Upper and lower endoscopic examination before surgery
--------------------------------------------------------

Using the electronic endoscopic system consisted of the EVIS-260 processor, the upper and lower endoscopic images were converted into a tagged image format using an EVIS LUCERA system (Olympus Optical, Tokyo, Japan). Any tumorous lesion that is suspicious for cancer was biopsied during the procedure. Characteristics including location and shape of the cancer were recorded.

3. Pathological analysis after surgical resection
-------------------------------------------------

The size of resected specimen was measured as the maximum diameter of cancer. Well differentiated adenocarcinomas were diagnosed when the gland-forming area encompassed over 95% of the high-power field, while poorly differentiated adenocarcinomas were diagnosed when it was less than 50%. Moderately differentiated adenocarcinomas were diagnosed when the gland-forming area were between 50% and 95%. If two different cell types are mingled, the diagnosis was made based on the predominant cell type. In gastric cancer, Lauren's classification of intestinal, diffuse, or mixed type were analyzed.

4. Analysis for MSI
-------------------

DNA preparation was performed as previously described in our study.[@b8-gnl-10-220],[@b11-gnl-10-220] With fluorescent dye-labeled primers of mononucleotide markers (BAT25 and BAT26) and dinucleotide markers (D2S123, D5S346, and D17S250), MSI was analyzed by polymerase chain reaction amplification. MSI was defined as a differently sized band in the tumor sample or a band shift in either of the two alleles. A high incidence of MSI (MSI-H) was defined as a detection of instability in more than 30% of markers, a low incidence of MSI (MSI-L) was defined as a detection of instability in less than 30% of markers, and microsatellite stability (MSS) was defined as no definite evidence of MSI.

5. Immunohistochemical stain for MMR proteins in colorectal cancer
------------------------------------------------------------------

Analysis for MMR proteins was performed as previously described in previous studies.[@b9-gnl-10-220],[@b11-gnl-10-220] Slides were deparaffinized in xylene and rehydrated in 100%, 95%, and 70% alcohols to water. The slides were immersed in sodium citrate buffer (pH 6.0) for hMLH1 or EDTA (PH 8.4 to 9.0) for hMSH2, hMSH6, hPMS2 and heated in an autoclave for antigen retrieval. Endogenous peroxidase activity was blocked by incubation with 3% H~2~O~2~ for 5 minutes. hMLH1 (Cell Marque, Rocklin, CA, USA), hMSH2 (Cell Marque), hMSH6 (Cell Marque), and hPMS2 (Cell Marque) antibodies were incubated for 1 hour. Slides were then processed using a DAKO Envision kit (DAKO Corp., Carpinteria, CA, USA) for hMLH1/hPMS2 and Optiview kit (Ventana, Tucson, AZ, USA) for hMSH2/hMSH6. The sections were incubated with 3,3-diaminobenzidine tetrahydrochloride and H~2~O~2~ for 3 minutes, counterstained with hematoxylin, dehydrated in graded alcohols, cleared in xylene, and coverslipped.

6. Immunostaining for mucin phenotypes in gastric cancer
--------------------------------------------------------

Analysis for mucin phenotypes was performed as previously described in our study.[@b20-gnl-10-220] Using the iVIEW DAB detection kit (Ventana Medical Systems Inc., Tucson, AZ, USA) by the Benchmark XT (Ventana Medical Systems Inc.), the immunohistochemical staining with primary antibodies, MUC5AC (45M/1; Neomarker, Fremont, CA, USA, 1:2,000), MUC6 (MCN6.01; Neomarker, 1:200), MUC2 (996/1; Neomarker, 1:2,000) and CD10 (56C6; Neomarker, 1:50) was carried out. Heat-induced antigen retrieval was carried out, and Hematoxylin was used for counterstaining. Gastric mucin phenotype was defined if more than 10% of cancer cells exhibited MUC5AC and/or MUC6. Intestinal mucin phenotype was defined if more than 10% of cancer cells exhibited MUC2 and/or CD10 markers. Mixed mucin phenotype was defined if more than 10% of neoplastic cells showed both gastric and intestinal markers. Unclassified mucin phenotype was defined if less than 10% of neoplastic cells showed gastric and intestinal markers.

7. Statistical analysis
-----------------------

Using PASW statistics 17.0 for windows (SPSS, Chicago, IL, USA), a p-value less than 0.05 was considered statistically significant. Continuous variables were compared by t-test and presented as mean±standard deviation. For the continuous values showing asymmetric distribution, Kruskal-Wallis test was used for the comparison between three groups (cancers with MSS, cancers with MSI-L, and cancers with MSI-H). Differences on clinicopathological factors among three groups (MSS, MSI-L, and MSI-H groups) were analyzed by one-way analyses of variance (ANOVAs) followed by Bonferroni post-hoc tests for numerical variables and chi-square tests for categorical variables. Presence or absence of synchronous GI neoplasm served as the primary exposure of interest. Logistic regression analysis was performed to determine the independent significant clinicopathological factors that showed a causal relationship with a dependent variable in cancer patients with synchronous GI neoplasm.

RESULTS
=======

1. Characteristics of the subjects
----------------------------------

A total of 595 patients were included, and one patient showed synchronous gastric and rectal cancers. Of 434 gastric cancer patients, 9.4% showed MSI-H and 4.8% showed MSI-L. Of 162 colorectal cancer patients, 9.3% showed MSI-H and 5.5% showed MSI-L ([Fig. 1](#f1-gnl-10-220){ref-type="fig"}). Double primary cancer was noticed in 21 (8 colon, 3 rectal, 2 lung, 2 breast, 1 esophagus, 1 thyroid, 1 liver, 1 pancreas, 1 ovary, and 1 cervical cancers) of 434 gastric cancer patients and 3 (1 gastric, 1 thyroid, and 1 lung cancers) of 162 colorectal cancer patients.

2. Gastric cancers according to the status of MSI
-------------------------------------------------

Of 434 gastric cancers, 372 showed MSS, 21 showed MSI-L, and 41 showed MSI-H ([Table 1](#t1-gnl-10-220){ref-type="table"}). Patients with MSI gastric cancer showed higher prevalence of synchronous colorectal cancer (4.8%, p=0.023), colorectal adenoma (11.3%, p=0.011), and gastric adenoma (3.2%, p=0.004) than those with MSS gastric cancers (0.5%, 3.2%, and 1.0%, respectively) ([Fig. 2](#f2-gnl-10-220){ref-type="fig"}). Prevalence of the synchronous colorectal adenoma was highest in MSI-L gastric cancers (19.0%) than those with MSI-H (7.3%) or MSS (3.2%) gastric cancers (p=0.002). In one-way ANOVA tests, the mean age was significantly different among the patients with MSS, MSI-L, and MSI-H gastric cancers ([Table 1](#t1-gnl-10-220){ref-type="table"}). Bonferroni post-hoc test exhibited that patients with MSI-H gastric cancer and those with MSI-L gastric cancer were older than those with MSS gastric cancer.

3. Synchronous GI neoplasm in gastric cancer patients
-----------------------------------------------------

Gastric cancers were reanalyzed according to the presence of synchronous GI neoplasm. Of all significant variables, logistic regression analysis between synchronous GI neoplasm and correlated variables revealed that presence of MSI was the only significant factor (p=0.004). According to the logistic regression analysis, age of the subject (p=0.059), size (p=0.736), location (p=0.303), and stage (p=0.326) of the gastric cancer were not significant for synchronous GI neoplasm in gastric cancer patients.

4. Colorectal cancers according to the status of MSI
----------------------------------------------------

Of 162 colorectal cancers, 138 showed MSS, 9 showed MSI-L, and 15 showed MSI-H ([Table 2](#t2-gnl-10-220){ref-type="table"}). There was no synchronous gastric adenoma in all three groups, and there was no significant difference in the prevalence of synchronous colorectal adenoma between the MSI-H (13.3%), MSI-L (11.1%), and MSS (12.3%) colorectal cancers (p=0.987). In one-way ANOVA tests, there were no significant differences between the patients with MSS, MSI-L, and MSI-H gastric cancers ([Table 2](#t2-gnl-10-220){ref-type="table"}).

5. Synchronous GI neoplasm in colorectal cancer patients
--------------------------------------------------------

In colorectal cancer patients, the presence of synchronous GI neoplasm was related to cell types and TNM staging. Neither MSI status nor MMR protein expression was related to the presence of synchronous GI neoplasm. There was no significant difference on the prevalence of colorectal adenoma between colon and rectal cancers according to the presence of MSI. Of 162 colorectal cancer patients, 23 showed abnormal MMR protein expression on immunohistochemical stain ([Table 3](#t3-gnl-10-220){ref-type="table"}). Of these 23 colorectal cancer patients, only three showed synchronous GI neoplasm, and only one showed extraintestinal cancer.

DISCUSSION
==========

The prevalence of synchronous colorectal cancer, colorectal adenoma, and gastric adenoma in this study was significantly higher among the patients with MSI-associated gastric cancers than in those with MSS-associated gastric cancers. In addition, the prevalence of synchronous colorectal adenoma was higher in MSI-L gastric cancers than in either MSI-H or MSS gastric cancers. However, the prevalence of synchronous colorectal adenoma did not differ significantly among MSI-H, MSI-L, and MSS colorectal cancers. These findings suggest that the role of MSI during carcinogenesis differs between the stomach and the colon. *Helicobacter pylori* infection is known to be associated with genetic instability leading to MSI-associated premalignant lesions.[@b21-gnl-10-220] Different from colorectal cancer, *H. pylori* infection leads to a deficiency of DNA MMR in gastric epithelial cells, which increases the risks of mutation and cancer.[@b21-gnl-10-220],[@b22-gnl-10-220] However, the suppressor pathway related to alterations in the p53, APC, and K-ras genes seems to be more important than the mutator pathway for colorectal carcinogenesis, especially for distal colon and rectal cancers.[@b3-gnl-10-220],[@b10-gnl-10-220]

Gastric cancers with MSI in the present study exhibited not only a higher prevalence of synchronous colorectal neoplasm, but also a higher prevalence of synchronous gastric adenoma than those without MSI. The tumor multiplicity of gastric neoplasms is believed to be related to the MMR system, which plays a role in the carcinogenesis of multiple gastric carcinomas and adenomas.[@b7-gnl-10-220],[@b23-gnl-10-220] Since MSI is associated with intestinal-type gastric cancer, the chances of developing a synchronous gastric neoplasm would be greater during chronic *H. pylori* infection. Therefore, care must be taken to determine the presence and development of synchronous and metachronous gastric neoplasms in gastric cancer patients with MSI. With regard to the frequency of synchronous colorectal neoplasm in patients with MSI-related gastric cancers, the present findings are consistent with those of previous studies showed that older gastric cancer patients or those with MSI have an increased risk of developing synchronous neoplasm.[@b13-gnl-10-220],[@b18-gnl-10-220]

Notably, the prevalence of synchronous GI neoplasms among all gastric cancer patients was highest in the MSI-L group in this study. Our finding is consistent with a previous study finding that the frequency of MSI-L was significantly higher in patients with multiple gastric cancers than in those with a single gastric cancer.[@b24-gnl-10-220] In the study, MSI-L was detected more frequently than MSI-H in patients with a single gastric cancer, synchronous multiple gastric cancers, or metachronous multiple gastric cancers. Another study of the incidence of MSI in patients with multiple primary GI cancers showed that patients with multiple cancers in different organs had a tendency to exhibit the MSI-L or MSS phenotypes.[@b25-gnl-10-220] Taken together, MSI-L is frequently accompanied by oncogene and tumor suppressor gene mutations during the slow process of gastric carcinogenesis, therefore increasing the risk of synchronous GI neoplasms.

With regard to the colorectal cancer patients, gastric cancer surveillance is recommended especially when the patient is old and male, has a positive family history of solid tumors, or lacks MSH2 expression in the cancer tissue.[@b26-gnl-10-220] Previous studies of synchronous neoplasms in GI cancers with MSI have revealed that patients with MMR defects tend to have neoplasms characterized by synchronous colorectal adenomas.[@b14-gnl-10-220],[@b15-gnl-10-220],[@b26-gnl-10-220] The frequency of MSI-H adenomas in patients with multiple colorectal cancers is known to be higher,[@b14-gnl-10-220] and MSI is more frequent in colorectal cancers with a double primary malignancy.[@b15-gnl-10-220] These findings are consistent with the present finding that MSI might be a predictor for detecting synchronous GI neoplasms. However, in this study, there was no significant correlation between synchronous colorectal adenoma and the presence of MSI in colorectal cancer. This suggests that synchronous colorectal adenoma occurs irrespective of MSI in colorectal cancer patients, and that the role of the suppressor pathway, which is related to chromosomal instability, is more important than that of the mutator pathway, which is related to MSI. Of the two subtypes of sporadic synchronous multiple colorectal cancers, right-sided colon cancers are related to multiple occurrences of consecutive MSI-H tumors, whereas the other types exhibits multiple occurrence irrespective of MSI.[@b27-gnl-10-220]

In the present study, more than half of the colorectal cancer patients with hMLH1 loss exhibited MSI-H. As suggested previously, methylation of the MLH1 gene promoter region may be an underlying cause of colorectal cancer with high MSI-H in patients without a germ-line mutation in an MMR gene.[@b28-gnl-10-220] In addition, our finding is consistent with a previous finding that the occurrence of GI neoplasms increases with age.[@b29-gnl-10-220] Since both aging and carcinogenesis show DNA damage and abnormal proteins, it is reasonable for synchronous GI neoplasm to occur more frequently in the elderly population. In the previous study, the proportion of gastric and colorectal carcinomas with hypermethylation of the hMLH1 promoter increased with age.[@b29-gnl-10-220] Gastric and colorectal cancers in elderly patients exhibited loss of hMLH1 expression, MSI, poorly differentiated histology, peri-tumoral inflammatory cell infiltration, low incidence of lymph node metastasis, and a favorable prognosis than those in young patients. The present study found gastric cancers with MSI to be related to old age. However, in colorectal cancer patients, MSI seems to be less strongly related to synchronous colorectal adenomas rather to chromosomal instability, which is linked to the development of most carcinomas.

The limitation of our study is that immunohistochemical stain for MMR protein was performed only for colorectal cancers and not for gastric cancers. For gastric cancers, MSI is not associated to MMR genetic alterations.[@b30-gnl-10-220] Therefore, we performed mucin phenotype analysis for gastric cancers instead of MMR protein analysis based on the previous studies.[@b5-gnl-10-220],[@b8-gnl-10-220],[@b9-gnl-10-220],[@b20-gnl-10-220],[@b30-gnl-10-220] In conclusion, MSI of gastric cancer is a predictor of synchronous colorectal neoplasm and gastric adenoma, and therefore both esophagogastroduodenoscopy and colonoscopy should be performed in these patients. On the other hand, synchronous colorectal adenoma occurs irrespective of MSI in colorectal cancer patients, suggesting that the suppressor pathway is more important than the mutator pathway in colorectal carcinogenesis.
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![Study flow. A total of 434 gastric cancers and 162 colorectal cancers were analyzed. One patient had synchronous gastric and rectal cancers.\
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![Prevalence of synchronous neoplasms according to the microsatellite instability (MSI) status in gastric cancer. Gastric cancer patients with MSI had a higher prevalence of synchronous colorectal cancer, colorectal adenoma, and gastric adenoma than those with microsatellite stable gastric cancers.](gnl-10-220f2){#f2-gnl-10-220}

###### 

Characteristics of MSS, MSI-L, and MSI-H Gastric Cancers

  Characteristic                                           Gastric cancers with MSS (n=372)   Gastric cancers with MSI-L (n=21)   Gastric cancers with MSI-H (n=41)   F            p-value
  -------------------------------------------------------- ---------------------------------- ----------------------------------- ----------------------------------- ------------ ---------
  Age, yr                                                  61.9±11.3                          66.8±14.7                           71.1±10.3                           6.79         0.001
  Male:female                                              251:121                            15:6                                29:12                               χ^2^=0.30    0.860
  Synchronous GI neoplasm                                                                                                                                                          
   Colorectal cancer                                       2 (0.5)                            2 (9.5)                             1 (2.4)                             χ^2^=14.75   0.001
   Colorectal adenoma                                      12 (3.2)                           4 (19.0)                            3 (7.3)                             χ^2^=12.82   0.002
   Gastric adenoma                                         4 (1.0)                            2 (9.5)                             0                                   χ^2^=11.07   0.004
  Cell type, WD:MD:PD:signet ring:mucinous                 39:137:118:65:13                   3:10:3:5:0                          2:25:10:3:1                         1.38         0.241
  Mucin phenotype, gastric:intestinal:mixed:unclassified   108:100:86:78                      9:4:7:1                             15:8:9:9                            1.86         0.136
  Location, antrum:corpus:fundus                           160:164:48                         9:8:4                               30:11:0                             4.44         0.012
  Size, cm[\*](#tfn3-gnl-10-220){ref-type="table-fn"}      3.6 (0.3--15.8)                    4.3 (1.2--23.0)                     4.6 (0.7--11.3)                     1.14         0.320
  T stage, T1:T2:T3:T4                                     232:40:53:47                       12:0:4:5                            16:13:7:5                           2.00         0.114
  N stage, N0:N1:N2:N3                                     253:44:28:47                       12:2:1:6                            24:10:3:4                           0.89         0.444
  M stage, M0:M1                                           360:12                             19:2                                39:2                                χ^2^=2.40    0.301
  TNM stage, I:II:III:IV                                   245:51:59:17                       11:3:3:4                            20:14:5:2                           0.95         0.415
  Microinvasion                                                                                                                                                                    
   Lymphatic invasion                                      119                                9                                   18                                  χ^2^=3.19    0.203
   Venous invasion                                         47                                 4                                   2                                   χ^2^=3.03    0.219
   Perineural invasion                                     75                                 6                                   5                                   χ^2^=2.54    0.281

Data are expressed as mean±SD, number (%), or median (range).

MSS, microsatellite stable; MSI-L, low incidence of microsatellite instability; MSI-H, high incidence of microsatellite instability; SD, standard deviation; GI, gastrointestinal; WD, well differentiated adenocarcinoma; MD, moderately differentiated adenocarcinoma; PD, poorly differentiated adenocarcinoma; signet ring, signet ring cell carcinoma (poorly-cohesive carcinoma); mucinous, mucinous adenocarcinoma.

Kruskal-Wallis test was used.

###### 

Characteristics of MSS, MSI-L, and MSI-H Colorectal Cancers

  Characteristic                             Colorectal cancers with MSS (n=138)   Colorectal cancers with MSI-L (n=9)   Colorectal cancers with MSI-H (n=15)   F            p-value
  ------------------------------------------ ------------------------------------- ------------------------------------- -------------------------------------- ------------ ---------
  Age, yr                                    63.0±11.8                             61.6±11.2                             63.3±10.1                              0.67         0.649
  Male:female                                86:52                                 3:6                                   8:7                                    χ^2^=3.25    0.860
  Synchronous GI neoplasm                                                                                                                                                    
   Colorectal adenoma                        17 (12.3)                             1 (11.1)                              2 (13.3)                               χ^2^=0.03    0.987
   Gastric adenoma                           0                                     0                                     0                                      \-           \-
  Cell type, WD:MD:PD:signet ring:mucinous   1:128:3:1:5                           1:7:0:0:1                             0:14:1:0:0                             0.25         0.862
  Location, right:left:RS junction:rectum    29:65:14:30                           6:1:0:2                               10:4:0:1                               2.01         0.116
  Size, cm                                   4.1 (0.3--10.5)                       5.0 (1.5--8.5)                        4.5 (0.3--11.5)                        0.45         0.638
  CEA, mg/dL                                 3.5 (0.5--601.3)                      2.6 (1.0--400.0)                      2.2 (0.8--12.3)                        0.52         0.595
  T stage, T1:T2:T3:T4                       13:12:98:15                           2:0:3:4                               2:3:8:2                                1.87         0.138
  N stage, N0:N1:N2:N3                       74:32:32                              3:2:4                                 11:4:0                                 0.85         0.431
  M stage, M0:M1                             114:24                                6:3                                   15:0                                   χ^2^=4.85    0.088
  TNM stage, I:II:III:IV                     20:52:42:24                           2:1:3:3                               4:7:4:0                                0.28         0.758
  Microinvasion                                                                                                                                                              
   Lymphatic invasion                        48                                    3                                     1                                      χ^2^=4.91    0.086
   Venous invasion                           8                                     2                                     0                                      χ^2^=5.02    0.081
   Perineural invasion                       37                                    4                                     1                                      χ^2^=4.56    0.102
  IHC results of MMR protein                                                                                                                                                 
   Loss of MLH1 expression                   8                                     0                                     9                                      χ^2^=42.16   \<0.001
   Loss of MSH2 expression                   2                                     0                                     4                                      χ^2^=23.78   \<0.001
   Loss of MSH6 expression                   1                                     0                                     4                                      χ^2^=29.89   \<0.001
   Loss of PMS2 expression                   8                                     0                                     8                                      χ^2^=34.33   \<0.001

Data are expressed as mean±SD, number (%), or median (range).

MSS, microsatellite stable; MSI-L, low incidence of microsatellite instability; MSI-H, high incidence of microsatellite instability; SD, standard deviation; GI, gastrointestinal; WD, well-differentiated adenocarcinoma; MD, moderately differentiated adenocarcinoma; PD, poorly differentiated adenocarcinoma; signet ring, signet ring cell carcinoma (poorly-cohesive carcinoma); mucinous, mucinous adenocarcinoma; RS, rectosigmoid; CEA, carcinoembryonic antigen; IHC, immunohistochemical stain; MMR, mismatch repair.

###### 

Clinicopathological Findings of Colorectal Cancers with Either MSI or Abnormal MMR Protein Expression

  Status of MSI   Age/sex   Location                Stage (TNM)   Cell type   MLH1     MSH2     MSH6     PMS2     Presence of synchronous neoplasm
  --------------- --------- ----------------------- ------------- ----------- -------- -------- -------- -------- ----------------------------------
  MSS             58/M      Rectum                  2 (T3N0M0)    MD          Loss     Intact   Intact   Loss     Colorectal adenoma
                  34/F      Left colon              1 (T2N0M0)    MD          Loss     Intact   Intact   Loss     None
                  55/M      Rectum                  1 (T2N0M0)    MD          Loss     Intact   Intact   Loss     None
                  59/M      Rectosigmoid junction   3 (T3N2M0)    MD          Loss     Intact   Intact   Loss     None
                  64/M      Rectum                  3 (T3N2M0)    MD          Loss     Intact   Intact   Loss     None
                  74/F      Left colon              3 (T3N2M0)    MD          Loss     Intact   Intact   Loss     None
                  81/M      Right colon             3 (T3N1M0)    MD          Loss     Intact   Intact   Loss     None
                  74/M      Rectum                  4 (T3N2M1)    MD          Loss     Intact   Intact   Loss     None
                  59/M      Right colon             2 (T3N0M0)    MD          Intact   Loss     Loss     Intact   None
                  52/F      Right colon             3 (T3N1M0)    MD          Intact   Loss     Intact   Intact   None
  MSI-H           45/M      Left colon              1 (T1N0M0)    MD          Loss     Intact   Intact   Loss     Colorectal adenoma
                  57/M      Right colon             2 (T3N0M0)    MD          Loss     Intact   Intact   Loss     Colorectal adenoma
                  65/F      Right colon             2 (T3N0M0)    MD          Loss     Intact   Intact   Loss     Thyroid cancer
                  51/F      Right colon             2 (T3N0M0)    MD          Loss     Intact   Intact   Loss     None
                  63/F      Right colon             1 (T2N0M0)    MD          Loss     Intact   Intact   Loss     None
                  72/F      Right colon             1 (T2N0M0)    MD          Loss     Intact   Intact   Loss     None
                  73/F      Left colon              3 (T2N1M0)    MD          Loss     Intact   Intact   Loss     None
                  74/M      Right colon             2 (T3N0M0)    MD          Loss     Intact   Intact   Loss     None
                  71/M      Right colon             2 (T3N0M0)    PD          Loss     Intact   Intact   Intact   None
                  54/F      Left colon              2 (T3N0M0)    MD          Intact   Loss     Loss     Intact   None
                  73/M      Right colon             3 (T3N1M0)    MD          Intact   Loss     Loss     Intact   None
                  79/M      Right colon             2 (T4N0M0)    MD          Intact   Loss     Loss     Intact   None
                  58/M      Right colon             3 (T3N1M0)    MD          Intact   Loss     Loss     Intact   None
                  55/M      Rectum                  1 (T1N0M0)    MD          Intact   Intact   Intact   Intact   None
                  59/F      Left colon              3 (T4N1M0)    MD          Intact   Intact   Intact   Intact   None
  MSI-L           71/F      Right colon             3 (T3N1M0)    MD          Intact   Intact   Intact   Intact   Colorectal adenoma
                  54/M      Right colon             1 (T1N0M0)    WD          Intact   Intact   Intact   Intact   None
                  57/M      Rectum                  1 (T1N0M0)    MD          Intact   Intact   Intact   Intact   None
                  61/F      Right colon             3 (T3N1M0)    Mucinous    Intact   Intact   Intact   Intact   None
                  65/F      Right colon             3 (T4N2M0)    MD          Intact   Intact   Intact   Intact   None
                  78/M      Right colon             2 (T4N0M0)    MD          Intact   Intact   Intact   Intact   None
                  68/F      Rectum                  4 (T3N2M1)    MD          Intact   Intact   Intact   Intact   None
                  61/F      Right colon             4 (T4N2M1)    MD          Intact   Intact   Intact   Intact   None
                  39/F      Left colon              4 (T4N2M1)    MD          Intact   Intact   Intact   Intact   None

MSI, microsatellite instability; MMR, mismatch repair; MSS, microsatellite stable; M, male; MD, moderately differentiated adenocarcinoma; F, female; MSI-H, high incidence of microsatellite instability; PD, poorly differentiated adenocarcinoma; MSI-L, low incidence of microsatellite instability; WD, well-differentiated adenocarcinoma; mucinous, mucinous adenocarcinoma.
